Reginster J Y, Jeugmans-Huynen A M, Albert A, Denis D, Franchimont P
Rheumatology, Physical Medicine and Rehabilitation Department, University of Liège, Belgium.
J Bone Miner Res. 1988 Jun;3(3):249-52. doi: 10.1002/jbmr.5650030302.
The effectiveness of synthetic salmon calcitonin (SCT) administered as a nasal spray was assessed via clinical, biological, and radiological variables in 17 previously untreated Pagetic patients over a 1-year course of therapy. The results showed a highly significant decrease of serum alkaline phosphatase (S-ALP) (p less than 0.05 after 1 month of treatment) and of the urinary hydroxyproline/creatinine ratio (OH/Cr) (p less than 0.01 after 1 month of treatment). For the whole group, the mean decrease in S-ALP was 37 +/- 4% (SEM) after 6 months (p less than 0.01) and 31 +/- 5% after 1 year (p less than 0.01). The mean fall in OH/Cr was 35 +/- 6% (SEM) (p less than 0.01) and 37 +/- 7% (p less than 0.01) after 6 and 12 months, respectively. None of the usual side-effects of SCT were reported and local tolerance was excellent throughout the study.
通过临床、生物学和放射学变量，对17名未经治疗的变形性骨炎患者在为期1年的治疗过程中使用鼻喷雾剂型的合成鲑鱼降钙素（SCT）的有效性进行了评估。结果显示，血清碱性磷酸酶（S-ALP）显著下降（治疗1个月后p<0.05），尿羟脯氨酸/肌酐比值（OH/Cr）也显著下降（治疗1个月后p<0.01）。对于整个组，S-ALP在6个月后的平均下降幅度为37±4%（标准误）（p<0.01），1年后为31±5%（p<0.01）。OH/Cr在6个月和12个月后的平均下降幅度分别为35±6%（标准误）（p<0.01）和37±7%（p<0.01）。在整个研究过程中，未报告SCT常见的副作用，且局部耐受性良好。
